Salute e Benessere
SiBionics' CGM Meets iCGM Special Control Criteria, Spotlighting Diabetes Solutions at EASD 2025
On the exhibition floor, SiBionics' next-generation devices — the and the — became focal points, drawing considerable attention from attendees. Visitors expressed strong interest in the products' technical strengths and clinical relevance, engaging in active dialogue with the SiBionics team about their advantages in real-world diabetes management.
Importantly, a feasibility study Recognized for their high accuracy and clinical reliability. The GS3 system demonstrated exceptional performance, particularly in the hypoglycemic range, surpassing iCGM requirements and reinforcing its value in supporting both clinical decision-making and patient self-management.
As a rising leader in continuous monitoring technologies — and currently the only company worldwide to commercialize CKM — SiBionics has showcased its strong R&D capabilities and pioneering vision. Looking ahead, the company will continue to expand its portfolio, driving innovation and delivering precise, high-quality solutions to improve outcomes for people with diabetes globally.
Founded in 2015, SIBIONICS is a leading medical device company headquartered in Shenzhen and Irvine. Specializing in biosensor innovation, the company integrates continuous monitoring technology, smart algorithms, and user-friendly software to enhance health management. With over 500 employees — 25% in R&D — SIBIONICS is committed to advancing personalized, data-driven care.
E- mail Address: Ravian.luo@sibionics.com
Photo - https://mma.prnewswire.com/media/2778015/DSC_7152.jpg
Logo - https://mma.prnewswire.com/media/2650570/Sibionics_logo____02_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/sibionics-cgm-meets-icgm-special-control-criteria-spotlighting-diabetes-solutions-at-easd-2025-302562379.html